- Free shipping on all orders over $200 (US) and $300 (International)
CJC-1295 and Ipamorelin were left off the 2026 FDA peptide review because they had already had their hearing. The FDA’s compounding advisory panel voted against both in late 2024: Ipamorelin on October 29 and CJC-1295 on December 4. Selank is a different case. It was named in RFK Jr.’s February 2026 announcement, but it is not among the 12 peptides the FDA actually sent to review, and the FDA has not publicly explained why.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said about 14 of the 19 peptides restricted in 2023 would move back toward legal compounding. Coverage of that announcement listed CJC-1295, Ipamorelin, Selank, AOD-9604 and Thymosin Alpha-1 alongside BPC-157, TB-500 and others.
The FDA’s formal action on April 15, 2026 was narrower. It removed 12 peptides from Category 2 because their original nominations were withdrawn, and sent those 12 to its advisory panel: seven in July 2026, five more before the end of February 2027.
| Peptide | Named in Feb 2026 coverage | Among the FDA’s 12 (April 2026) | 2026–27 panel review |
|---|---|---|---|
| CJC-1295 | Yes | No | None (voted down Dec 2024) |
| Ipamorelin | Yes | No | None (voted down Oct 2024) |
| AOD-9604 | Yes | No | None (voted down Dec 2024) |
| Thymosin Alpha-1 | Yes | No | None (voted down Dec 2024) |
| Selank | Yes | No | None scheduled |
| BPC-157 | Yes | Yes | July 2026: recommended |
| Semax | Yes | Yes | July 2026: recommended |
| GHK-Cu (injectable) | Yes | Yes | Before end of Feb 2027 |
The gap between the announcement and the FDA’s list is where most of the online confusion comes from.
Both peptides already went before the FDA’s compounding advisory panel in 2024, and the panel voted against both almost unanimously.
That review happened after two companies, Evexias and Farmakeio, sued the FDA over the 2023 restrictions on four peptides: CJC-1295, Ipamorelin, AOD-9604 and Thymosin Alpha-1. The FDA then sent all four to the panel.
| Peptide form | Meeting | Vote (yes / no / abstain) |
|---|---|---|
| Ipamorelin (free base) | October 29, 2024 | 0 / 12 / 1 |
| Ipamorelin acetate | October 29, 2024 | 0 / 12 / 1 |
| CJC-1295 (free base) | December 4, 2024 | 0 / 13 / 0 |
| CJC-1295 acetate | December 4, 2024 | 1 / 12 / 0 |
| CJC-1295 DAC (free base) | December 4, 2024 | 0 / 13 / 0 |
| CJC-1295 DAC acetate | December 4, 2024 | 0 / 13 / 0 |
| CJC-1295 DAC trifluoroacetate | December 4, 2024 | 0 / 13 / 0 |
Every CJC-1295 form was voted down, with and without DAC. If you want the difference between those two versions, see CJC-1295 DAC vs no DAC. Panel members said there was not enough data on safety and effectiveness.
The same two meetings also voted against AOD-9604 (0 to 12), Thymosin Alpha-1 (4 to 17) and Kisspeptin-10 (0 to 11).
The FDA has not explained why these peptides were left out of the 2026 batch. But the pattern is clear. The 2026 batch was made up of peptides whose nominations were withdrawn in April 2026. CJC-1295 and Ipamorelin had already had a full hearing, and lost.
Selank acetate was one of the peptides the FDA placed in Category 2 in September 2023. It was also named in coverage of the February 2026 announcement.
But Selank is not among the 12 peptides the FDA moved to review in April 2026. It is not on the July 2026 agenda or the February 2027 agenda, and we could not find any FDA notice explaining why.
That puts Selank on a different track from Semax, its closest relative. The panel voted 8 to 5, with 1 abstention, to recommend Semax in July 2026. If you research both, check their status separately. Our Semax vs Selank guide covers how the two compare.
If you search “is CJC-1295 legal in 2026”, you will find conflicting answers. There are three main reasons:
The reliable way to check any peptide’s status is the FDA itself: its Category 2 page, the advisory committee meeting pages and minutes, and the Federal Register for proposed rules.
Researching related growth hormone peptides? See Ipamorelin vs GHRP-6 and Sermorelin vs Tesamorelin. Tesamorelin is the one FDA-approved drug in that group.
None of this changes anything for research-use-only materials, which sit outside the compounding system. See what research use only means.
No. CJC-1295 was not part of the 2026 review. The FDA’s advisory panel voted against every CJC-1295 form in December 2024.
No. Ipamorelin was not among the peptides the FDA moved in 2026. The panel voted 0 to 12, with 1 abstention, against it in October 2024.
Not in 2026, and it is not on the agenda for the next meeting before the end of February 2027.
His February 2026 announcement described a broad group of about 14 peptides. The FDA’s formal action in April 2026 was narrower and covered a different set of 12 peptides.
BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, in July 2026. More on two of them: Epitalon’s FDA status and BPC-157 arginate vs acetate.
Five more peptides go before the panel before the end of February 2027. See the FDA’s next peptide review.
